NASDAQ:KZIA

Kazia Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy KZIA

*Your capital is at risk

$10.95

-0.84 (-7.12%)

At Close: Jun 03, 2026

Kazia Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 16.48M and sold 487.89K KZIA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	16.48M shares
● Sell	487.89K shares
74% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 13, 2026 Buy	Common Stock J-Other	Rao Sudha Officer	Officer	0 Value: $0
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Davidson Ebru Director	Director	2 000 Value: $670
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Davidson Ebru Director	Director	75 000 Value: $600.0K
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Friend John E. Ii Chief Executive Officer	CEO / President	30 000 Value: $565.5K
Mar 18, 2026 Buy	Ordinary Shares Option (Right to Buy)	Cain David Director, Cmc	Officer	400 000 Value: $42.4K
Mar 18, 2026 Buy	Ordinary Shares Option (Right to Buy)	Cain David Director, Cmc	Officer	100 000 Value: $66.5K
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Cain David Director, Cmc	Officer	100 000 Value: $800.0K
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Cain David Director, Cmc	Officer	5 000 Value: $95.0K
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Apple Robert F Director	Director	75 000 Value: $493.5K
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Apple Robert F Director	Director	2 000 Value: $670
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Bonacorda Jeffrey Vp, Finance And Controller	Officer	100 000 Value: $658.0K
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Bonacorda Jeffrey Vp, Finance And Controller	Officer	5 000 Value: $1K
Mar 18, 2026 Buy	Ordinary Shares Option (Right to Buy)	Simpson Jeremy Program Director	Officer	100 000 Value: $66.5K
Mar 18, 2026 Buy	Ordinary Shares Option (Right to Buy)	Simpson Jeremy Program Director	Officer	280 000 Value: $29.7K
Mar 18, 2026 Buy	Ordinary Shares Option (Right to Buy)	Friend John E. Ii Chief Executive Officer	CEO / President	1 000 000 Value: $106.1K
Mar 18, 2026 Buy	Ordinary Shares Option (Right to Buy)	Friend John E. Ii Chief Executive Officer	CEO / President	3 000 000 Value: $396.9K
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Friend John E. Ii Chief Executive Officer	CEO / President	500 000 Value: $3.29M
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Friend John E. Ii Chief Executive Officer	CEO / President	30 000 Value: $11.3K
Mar 18, 2026 Buy	American Depositary Shares	Coffey Steven R. S. Director	Director	1 122 Value: $8K
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Coffey Steven R. S. Director	Director	75 000 Value: $600.0K
Mar 18, 2026 Buy	American Depositary Share Option (Right to Buy)	Coffey Steven R. S. Director	Director	1 000 Value: $335
Mar 18, 2026 Buy	Ordinary Shares	Coffey Steven R. S. Director	Director	0 Value: $0
Nov 05, 2013 Sell	Sponsored ADRs, each convertible into 25 ordinary shares S-Sale	Austin Josiah T 10 Percent Owner	10% Owner	23 922 Value: $143.7K
Nov 05, 2013 Sell	Sponsored ADRs, each convertible into 25 ordinary shares S-Sale	Austin Josiah T 10 Percent Owner	10% Owner	23 922 Value: $143.7K
Nov 04, 2013 Sell	Sponsored ADRs, each convertible into 25 ordinary shares S-Sale	Austin Josiah T 10 Percent Owner	10% Owner	25 400 Value: $153.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT KAZIA THERAPEUTICS LIMITED

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Thera...

Read Full Profile Here